Clinical Trial Update: 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing 5 mcg and 10 mcg doses of tiotropium delivered by Respimat against placebo and ipratropium MDI in chronic obstructive pulmonary diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Ipratropium MDI (ipratropium)
• Tiotropium (Respimat) 10 mcg (tiotropium)
• Tiotropium (Respimat) 5 mcg (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED